Business Description
Aptose Biosciences Inc
NAICS : 325412
SIC : 3741
ISIN : CA03835T2002
Description
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | -0.84 | |||||
| Debt-to-Equity | -1.17 | |||||
| Debt-to-EBITDA | -0.3 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 7.3 | |||||
| 3-Year EPS without NRI Growth Rate | 7.6 | |||||
| 3-Year FCF Growth Rate | -3.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 36.32 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.64 | |||||
| 9-Day RSI | 45.55 | |||||
| 14-Day RSI | 46.38 | |||||
| 6-1 Month Momentum % | -70.85 | |||||
| 12-1 Month Momentum % | -91.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.05 | |||||
| Quick Ratio | 1.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | -141.87 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -261.01 | |||||
| ROIC % | -2481.86 | |||||
| 3-Year ROIIC % | -564.93 | |||||
| ROC (Joel Greenblatt) % | -3200.6 | |||||
| ROCE % | -2881.63 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.17 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | -0.17 | |||||
| EV-to-Forward-EBITDA | -0.01 | |||||
| EV-to-FCF | -0.16 | |||||
| Earnings Yield (Greenblatt) % | -588.24 | |||||
| FCF Yield % | -265.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aptose Biosciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.724 | ||
| Beta | -0.1 | ||
| Volatility % | 73.78 | ||
| 14-Day RSI | 46.38 | ||
| 14-Day ATR (€) | 0.013385 | ||
| 20-Day SMA (€) | 0.2128 | ||
| 12-1 Month Momentum % | -91.38 | ||
| 52-Week Range (€) | 0.132 - 2.08 | ||
| Shares Outstanding (Mil) | 60.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aptose Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aptose Biosciences Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aptose Biosciences Inc Frequently Asked Questions
What is Aptose Biosciences Inc(FRA:LTI)'s stock price today?
The current price of FRA:LTI is €0.21. The 52 week high of FRA:LTI is €2.08 and 52 week low is €0.13.
When is next earnings date of Aptose Biosciences Inc(FRA:LTI)?
The next earnings date of Aptose Biosciences Inc(FRA:LTI) is 2025-03-26 Est..
Does Aptose Biosciences Inc(FRA:LTI) pay dividends? If so, how much?
Aptose Biosciences Inc(FRA:LTI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers